Subscribe
shutterstock_1396958186_pavel_kapysh
Pavel Kapysh / Shutterstock.com
1 March 2022Big PharmaMuireann Bolger

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Moderna hits Pfizer and BioNTech with COVID-19 vaccine patent suit
30 August 2022   Moderna has taken Pfizer and its German partner BioNTech to court, alleging that the pair copied Moderna’s technology when developing their COVID-19 vaccine.
Americas
US govt wades into Moderna COVID row
15 February 2023   The pharma company is accused of using patented tech for a drug-delivery system without authorisation | Moderna sought to escape the suit by claiming that its contract with the US government conferred immunity.
Americas
Moderna secures COVID-19 vaccine delivery win before appeals court
12 April 2023   Biotech fails to convince Federal Circuit to overturn PTAB finding | Invalidation of patent related to “Non-liposomal systems for nucleic acid delivery”.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Moderna hits Pfizer and BioNTech with COVID-19 vaccine patent suit
30 August 2022   Moderna has taken Pfizer and its German partner BioNTech to court, alleging that the pair copied Moderna’s technology when developing their COVID-19 vaccine.
Americas
US govt wades into Moderna COVID row
15 February 2023   The pharma company is accused of using patented tech for a drug-delivery system without authorisation | Moderna sought to escape the suit by claiming that its contract with the US government conferred immunity.
Americas
Moderna secures COVID-19 vaccine delivery win before appeals court
12 April 2023   Biotech fails to convince Federal Circuit to overturn PTAB finding | Invalidation of patent related to “Non-liposomal systems for nucleic acid delivery”.

More on this story

Americas
Moderna hits Pfizer and BioNTech with COVID-19 vaccine patent suit
30 August 2022   Moderna has taken Pfizer and its German partner BioNTech to court, alleging that the pair copied Moderna’s technology when developing their COVID-19 vaccine.
Americas
US govt wades into Moderna COVID row
15 February 2023   The pharma company is accused of using patented tech for a drug-delivery system without authorisation | Moderna sought to escape the suit by claiming that its contract with the US government conferred immunity.
Americas
Moderna secures COVID-19 vaccine delivery win before appeals court
12 April 2023   Biotech fails to convince Federal Circuit to overturn PTAB finding | Invalidation of patent related to “Non-liposomal systems for nucleic acid delivery”.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?